ANABIOS CORPORATION

San Diego, CA · Medtech · Still private

MyoBLAZER™, an imaging-based platform for high-throughput contractility measurements of human primary cardiomyocytes to assess drug-induced cardiac toxicity

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · anabios.com

Sector: Medtech
Headquarters: San Diego, CA
Total capital: $4.7M

Federal grants: $4.7M; 5 awards · 2016–2021; Rank in peer group#36 of 112
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 2; 6 pending · first 2020; Rank in peer group#26 of 112

Capital timeline

Latest events

Sep 2021Federal grantHealth and Human S · Phase II · Development of a novel analgesic for mixed inflammatory and neuropathic pain states$1.7M
Sep 2020Federal grantHealth and Human S · Phase I · Development of a novel translational pain-drug screening platform for the generation of human-relevant data in preclinical pain drug discovery$320K
Mar 2020Federal grantHealth and Human S · Phase II · Development of an Integrated Platform for the Use of Adult Human Primary Cardiomyocytes in Preclinical Safety Assessment$1.1M
Jun 2017Federal grantHealth and Human S · Phase II · Validation and qualification of an ex vivo human cardiac tissue-based assay for the assessment of the potential cardiotoxicity of pharmaceutical compounds$550K
Jul 2016Federal grantHealth and Human S · Phase II · Validation and qualification of an ex vivo human cardiac tissue-based assay for the assessment of the potential cardiotoxicity of pharmaceutical compounds$945K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 112 peers

Line = median

Medtech · Instrument

Federal grants#36 · top 32%
Granted patents#26 · top 23%
Linked publications#2 · top 2%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Andrea P. GhettiResearcherExecutive OfficerLinked by 1 patent · $3.5M in grants as PI
Andre GhettiExecutive OfficerNamed in SEC Form D filings
George E GoldsmithExecutive OfficerNamed in SEC Form D filings
Ian WisenbergExecutive OfficerNamed in SEC Form D filings
Jack ReynoldsExecutive Officer, DirectorNamed in SEC Form D filings
Martin E WatersExecutive OfficerNamed in SEC Form D filings

Show all 10 people

Paul MillerExecutive OfficerNamed in SEC Form D filings
Peter E CrowleyExecutive Officer, DirectorNamed in SEC Form D filings
Richard E ErdmanDirectorNamed in SEC Form D filings
Stephen F. FlaimDirectorNamed in SEC Form D filings

What it has protected

USPTO · 2 granted of 8

Mar 23, 2021GrantedMethod For The Identification Of Sensory Neuron Subtypes In Ex Vivo PreparationsUSPTOUS 10,955,409
Oct 6, 2020GrantedSystem and Methods for Predicting Drug-Induced Inotropic and Pro-Arrhythmia RiskUSPTOUS 10,794,897
PendingMethod For The Identification Of Sensory Neuron Subtypes In Ex Vivo PreparationsUSPTOApplication PCTUS2018028421

Show all 8 patent records

Method For The Identification Of Sensory Neuron Subtypes In Ex Vivo PreparationsMar 23, 2021 · US 10,955,409Granted
System and Methods for Predicting Drug-Induced Inotropic and Pro-Arrhythmia RiskOct 6, 2020 · US 10,794,897Granted
Method For The Identification Of Sensory Neuron Subtypes In Ex Vivo PreparationsApplication PCTUS2018028421Pending
System And Methods For Predicting Drug-induced Inotropic And Pro-arrhythmia RiskApplication PCTUS2018016504Pending
Method for The Identification of Sensory Neuron Subtypes in Ex Vivo PreparationsApplication 62488667Pending
Therapeutic Uses Of Cardiac Myosin InhibitorsApplication PCTUS2023031932Pending
System and Methods for Predicting Drug-Induced Inotropic and Pro-Arrhythmia RiskApplication 62454786Pending
Therapeutic Uses Of Cardiac Myosin InhibitorsApplication 63403547Pending

Recent research by its founders

A Comprehensive Metric for ‘Spike’ Related Effects in Single Chalcogenide Xpoint Memory20260 cites
Microscopic model of the operation of the Single-chalcogenide X-point Memory20250 cites
VT Window Model of the Single-Chalcogenide Xpoint Memory (SXM)20246 cites

ION CHANNEL PHARMACOLOGY LLCSimilar federal contract value in Medtech · null in contracts
Radiant Images Inc.Similar federal contract value in Medtech · null in contracts
Haima Therapeutics, LLCSimilar federal contract value in Medtech · null in contracts
INVIBRAGEN INC.Similar federal contract value in Medtech · null in contracts
ALBA-TECHNIC, LLCSimilar federal contract value in Medtech · null in contracts
INHERENT TARGETING, LLCSimilar federal contract value in Medtech · null in contracts

Regulatory activity · Medtech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.